Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Avid Bioservices $160 million convertible senior notes offering
The convertible notes are due 2029
REGENXBIO $140 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
iRhythm Technologies $661.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029
Roche Holdings $3.875 billion notes offering
We advised Roche on the Rule 144A / Regulation S offering comprising four tranches of notes
Tandem Diabetes Care $316.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029
LivaNova $345 million convertible notes offering and capped call transactions
The 2.5% convertible senior notes are due 2029
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cardinal Health $1.15 billion notes offering
The investment-grade notes are due 2029 and 2034
Prime Medicine $161 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Market